These are certainly exciting times for us. Since becoming part of Actavis we have an even broader portfolio and a stronger pipeline of new products. We are constantly looking for new ways to grow and develop the business. The recent acquisition of Sindan opens up oncology and moves us into a whole new area with a relatively high number of products coming off patent in the next few years. We are extending our specialized hospital franchise so that we can really take advantage of these opportunities.
We value the unique partnerships we’ve forged with the National Pharmacy Association (NPA) and the Company Chemists Association (CCA) and are driving through a programme of POM to P switches to boost our OTC offering. The role of pharmacists is changing and our expert sales teams are there to offer the very best advice on adapting to the new contract and maximizing returns.
Actavis UK is ambitious and hungry for success. Our goal is to become the champion of first class generics. That’s not just about being the first choice of our customers, it’s also about being the most innovative and having the very best people. We’re certain that we’ve hit upon the winning formula. Now it’s up to us to deliver.